Skip to main content

Table 1 Baseline demographics

From: Cumulative effect of simvastatin, l-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in Alzheimer’s disease

Baseline characteristics Included subjects (n=10)
Age in years 67 (7)
Gender 60% women, 40% men
Hypertension 40%
Coronary artery disease 0%
Hyperlipidemia 10%
Baseline cognitive assessment
 Mini-Mental State Examination 24 (3)
 Cognitive Assessment Screening Test 29.6 (5)
 Clinical Dementia Rating scale 1 (0.47)
 ADAS-cog 13 31 (7)
Serology
 C-reactive protein (mg/L) 1.4 (1.8)
 Low-density lipoprotein (mg/dL) 137.2 (26.7)
 High-density lipoprotein (mg/dL) 58.2 (19.2)
 Total cholesterol (mg/dL) 223.9 (32.3)
 Triglycerides (mg/dL) 133.1 (66.9)
 Creatine phosphokinase (U/L) 69 (36.86)
 Thyroid-stimulating hormone (mU/L) 2.92 (2.33)
 Vitamin B12 (pg/mL) 506 (359)
 Erythrocyte sedimentation rate (mm/h) 8.8 (5.9)
 International normalized ratio 1.0 (0.1)
Medication use
 Donepezil or rivastigmine 80%
 Memantine 40%
 Psychotropic use 70%
 Anticholinergic drug usea 30%
Apolipoprotein E (APOE) genotyping (n=9)
 APOE-3,3 1 (11%)
 APOE-3,4 5 (56%)
 APOE-4,4 3 (33%)
Cerebral spinal fluid phosphorylated tau (n=7)
 High (>68 pg/mL) 3(43%)
 Intermediate (55–67 pg/mL) 1 (14%)
 Normal (<54 pg/mL) 3 (43%)
  1. ADAS-cog 13 indicates Alzheimer’s Disease Assessment Scale-cognitive 13. Data are shown as mean±sd or %. aMost commonly diphenhydramine